WPC-262

GPTKB entity

Properties (61)
Predicate Object
gptkbp:instanceOf chemical compound
gptkbp:chemicalFormula C12H14N2O3S
gptkbp:hasAwards bacterial infections
gptkbp:hasFacility soluble in water
gptkbp:hasFilm nausea
gptkbp:hasHistory 4 hours
gptkbp:hasPerformedAt tablet
gptkbp:hasWeight 270.32 g/mol
https://www.w3.org/2000/01/rdf-schema#label WPC-262
gptkbp:isAssociatedWith specific pathogens
gptkbp:isAttendedBy gptkb:FDA
adults
oral route
gptkbp:isAvailableIn various strengths
gptkbp:isAvenueFor pharmacokinetics
gptkbp:isChallengedBy liver enzymes
gptkbp:isCompatibleWith stable at room temperature
gptkbp:isConsidered treatment guidelines
gptkbp:isDocumentedIn clinical guidelines
scientific literature
gptkbp:isEvaluatedBy patient outcomes
safety profile
gptkbp:isFeaturedIn long-term use
gptkbp:isFocusedOn pharmacopoeia
gptkbp:isIncorporatedIn pediatric patients
gptkbp:isInformedBy excipients
gptkbp:isInvolvedIn drug resistance
gptkbp:isKnownFor broad-spectrum activity
gptkbp:isMarketedAs brand name A
gptkbp:isPartOf placebo controls
drug formulation
chronic infections
antibiotic stewardship programs
other antibiotics
antibiotic therapy.
new antibiotic classes
gptkbp:isPortrayedBy case studies
gptkbp:isRecognizedBy medical community
gptkbp:isRecognizedFor specific infections
gptkbp:isRelatedTo antibiotics
gptkbp:isStudiedIn animal models
antimicrobial activity
resistance mechanisms
new therapeutic areas
gptkbp:isSubjectTo regulatory approval
gptkbp:isSuitableFor precursor compounds
gptkbp:isTrainedIn placebo
gptkbp:isUsedFor efficacy
other drugs
gptkbp:isUsedIn pharmaceuticals
treatment regimens
gptkbp:isUtilizedFor synergistic effects
new formulations
gptkbp:isUtilizedIn clinical trials
clinical settings
treatment protocols
various populations
gptkbp:isValuedFor skin infections
gptkbp:isVisitedBy gptkb:XYZ_Pharmaceuticals
gptkbp:numberOfFigures 123456-78-9
gptkbp:training pregnancy